Retinal Vessel Density and Retinal Nerve Fiber Layer Thickness: A Prospective Study of One-Year Follow-Up of Patients with Parkinson's Disease.
Parkinson disease
optical coherence
retina
tomography
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
06
2023
accepted:
14
08
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
This study aims to compare the superficial vascular density from the macular region and the retinal nerve fiber layer (RNFL) thickness from the optic disc region between Parkinson's disease (PD) patients and controls. We enrolled 56 idiopathic PD patients, totaling 86 eyes (PD group), and 45 sex- and age-matched healthy individuals, amounting to 90 eyes (control group). All subjects underwent examination using Zeiss wide-field vascular optical coherence tomography (OCT) (Cirrus HD-OCT 5000 Carl Zeiss, Germany), with a scanning range of 3 mm × 3 mm. We divided the images into two concentric circles with diameters of 1 mm and 3 mm at the macular fovea's center. Patients with PD were evaluated during their "off" phase using the Unified Parkinson's Disease Rating Scale III (UPDRS-III) and the Hoehn-Yahr scale (H-Y scale) to assess disease severity. The PD group exhibited significantly lower RNFL thickness (106.13±12.36 μm) compared to the control group (115.95±11.37 μm, P < 0.05). Similarly, the superficial retinal vessel length density was significantly lower in the PD group (20.7 [19.62, 22.17] mm PD patients show retinal structural damage characterized by RNFL thinning and reduced retinal vessel length density. However, RNFL thickness did not correlate with vascular density nor did it decrease with the disease's progression.
Identifiants
pubmed: 37637710
doi: 10.2147/IJGM.S426501
pii: 426501
pmc: PMC10460207
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3701-3712Informations de copyright
© 2023 Tu et al.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Acta Neuropathol. 2019 Mar;137(3):379-395
pubmed: 30721408
Eur J Ophthalmol. 2021 Nov;31(6):2808-2817
pubmed: 34000876
J Mol Neurosci. 2020 Aug;70(8):1169-1176
pubmed: 32180111
Curr Eye Res. 2021 Dec;46(12):1886-1891
pubmed: 34348531
Mov Disord Clin Pract. 2022 Feb 16;9(3):284-295
pubmed: 35402641
Front Med (Lausanne). 2022 Sep 15;9:957700
pubmed: 36186761
Eur J Ophthalmol. 2014 Jan-Feb;24(1):114-9
pubmed: 23828323
Nat Immunol. 2023 Apr;24(4):700-713
pubmed: 36807640
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Quant Imaging Med Surg. 2020 Oct;10(10):1930-1939
pubmed: 33014726
PLoS One. 2012;7(4):e34823
pubmed: 22536333
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1151-1157
pubmed: 28208185
JAMA Ophthalmol. 2021 Feb 1;139(2):182-188
pubmed: 33355613
Mov Disord. 2014 Jan;29(1):68-74
pubmed: 24458320
Hum Brain Mapp. 2023 May;44(7):2701-2711
pubmed: 36852616
Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1217-28
pubmed: 10752963
Molecules. 2021 Mar 10;26(6):
pubmed: 33802165
Ann Neurol. 2019 Oct;86(4):572-581
pubmed: 31464350
Front Neurosci. 2020 Oct 02;14:588515
pubmed: 33132836
Nat Rev Neurol. 2013 Jan;9(1):44-53
pubmed: 23165340
J Neurol. 2021 Feb;268(2):549-558
pubmed: 32865628
Mov Disord. 2021 Dec;36(12):2940-2944
pubmed: 34390510
Ideggyogy Sz. 2021 Jan 30;74(1-2):57-63
pubmed: 33497054
Cureus. 2021 Jul 7;13(7):e16224
pubmed: 34367824
Aging Dis. 2021 Aug 1;12(5):1211-1222
pubmed: 34341703
Prog Retin Eye Res. 2021 Sep;84:100951
pubmed: 33516833
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4115-4122
pubmed: 30098201
Ann Neurol. 2014 Jun;75(6):964-6
pubmed: 24816946
Front Neurol. 2017 Dec 22;8:710
pubmed: 29312131
Sci Rep. 2020 Jun 15;10(1):9619
pubmed: 32541823
Int Ophthalmol. 2019 Jun;39(6):1255-1262
pubmed: 29744762
Front Aging Neurosci. 2021 Oct 20;13:749026
pubmed: 34744690
Parkinsonism Relat Disord. 2021 Jul;88:40-45
pubmed: 34118642
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Ophthalmol Retina. 2017 Sep-Oct;1(5):435-447
pubmed: 29034359
Cell Mol Life Sci. 2021 May;78(9):4417-4433
pubmed: 33782712
Ann Clin Transl Neurol. 2015 Feb;2(2):196-201
pubmed: 25750923
J Parkinsons Dis. 2018;8(1):85-92
pubmed: 29480221
Mov Disord. 2018 Sep;33(9):1390-1406
pubmed: 30311977
J Neurol. 2021 Dec;268(12):4646-4654
pubmed: 33174132
Retina. 2020 Aug;40(8):1483-1491
pubmed: 31479087
Br J Ophthalmol. 2014 Mar;98(3):350-5
pubmed: 24276697
Acta Neuropathol Commun. 2016 Aug 18;4(1):86
pubmed: 27535749
Sci Rep. 2021 Jan 13;11(1):1120
pubmed: 33441868
J Neurol Sci. 2023 Aug 15;451:120730
pubmed: 37454572
Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):24
pubmed: 35050306